rs66791338 — IVD 5-bp IVD regulatory region indel

Intronic 5-bp indel (AAAGG) in the IVD regulatory region that is the primary functional variant controlling IVD expression; the derived deletion allele drives higher enzyme activity and lower isovalerylcarnitine, and is enriched in East Asian populations under positive selection

See your personal result for IVD

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IVD rs66791338 — The Regulatory Indel That Defines Leucine Catabolism Efficiency

Every gram of dietary leucine — the most anabolic amino acid, abundant in meat, dairy, and protein powders — is funnelled through a five-step mitochondrial enzymatic cascade before it can be burned for energy or converted to acetyl-CoA. The third and rate-limiting step belongs to isovaleryl-CoA dehydrogenase (IVD)11 isovaleryl-CoA dehydrogenase (IVD)
A mitochondrial flavoenzyme that converts isovaleryl-CoA to 3-methylcrotonyl-CoA, consuming one molecule of FAD per reaction; named for the sweaty-feet odor of isovaleric acid that accumulates when IVD fails. When IVD runs efficiently, leucine flows cleanly through to energy. When it stalls, the metabolic intermediate isovalerylcarnitine (C5-carnitine)22 isovalerylcarnitine (C5-carnitine)
A blood and urine metabolite that directly reflects IVD enzyme activity; the primary neonatal screening marker for isovaleric acidemia; measured as part of acylcarnitine panels rises.

rs66791338 is not a coding variant — it sits within an intron of IVD, 5 base pairs of sequence (AAAGG) either present or absent. Yet this tiny structural difference is the primary functional variant at the IVD locus33 primary functional variant at the IVD locus
Confirmed by Brown et al. 2024 (PMID 37930192) using luciferase reporter assays and CRISPR/Cas9 homology-directed repair in lymphoblastoid cell lines, directly controlling how much IVD protein the cell produces. The deletion allele (−AAAGG) is the derived form that arose more recently in human evolutionary history — and it is better. It increases IVD expression, accelerates leucine catabolism, and is under positive selection in Japanese populations, where it reaches ~80% frequency compared to ~22% in Africans.

The Mechanism

The five base pairs at rs66791338 fall within an intronic enhancer44 intronic enhancer
A non-coding DNA element that binds transcription factors and boosts nearby gene transcription; enhancers can act across thousands of base pairs from the promoter that regulates IVD transcription. The insertion allele (I) disrupts enhancer geometry or transcription factor binding, reducing IVD mRNA output. The deletion allele (D) restores or optimizes the enhancer, driving higher IVD expression.

IVD itself is a flavoprotein55 flavoprotein
An enzyme that requires FAD (flavin adenine dinucleotide), derived from riboflavin (vitamin B2), as a tightly bound cofactor for catalytic activity. In riboflavin-deficient mitochondria, IVD activity can fall to 17% of control levels66 17% of control levels
Measured in rat liver mitochondria; the mature enzyme degrades rapidly without FAD stabilization, independent of gene expression level. This creates a compounding vulnerability: if the I allele already reduces IVD expression, and riboflavin intake is marginal, enzyme activity can fall through two independent mechanisms simultaneously.

Brown et al. 2024 showed the deletion allele associates with a 0.088 unit decrease in isovalerylcarnitine77 0.088 unit decrease in isovalerylcarnitine
Normalized to propionylcarnitine in 4,678 TwinsUK participants; r²=0.40, P<2×10⁻¹⁶ for the correlation between variant-expression associations and variant- metabolite associations. Lower isovalerylcarnitine reflects more efficient substrate processing — the metabolic equivalent of a clean-running combustion cycle.

The Evidence

The functional case for rs66791338 as the causal regulatory variant rests on two pillars. First, luciferase reporter assays88 luciferase reporter assays
Placing the variant sequence upstream of a reporter gene and measuring light output as a proxy for transcriptional activity; the gold standard for testing regulatory variant function directly demonstrated that the deletion allele drives higher enhancer activity. Second, CRISPR/Cas9 homology-directed repair experiments — converting endogenous insertions to deletions and vice versa in cell lines — confirmed that the indel causally changes IVD mRNA levels, not merely correlates with them. This bidirectional experimental confirmation is rare for regulatory variants in complex disease genetics.

The population genomics case is equally striking. The JPT (Japanese from Tokyo) population99 JPT (Japanese from Tokyo) population
One of the East Asian populations in the 1000 Genomes Project; used as a reference for East Asian ancestry in population genetics shows a positive selection peak centered on the IVD locus, suggesting the high-expression deletion haplotype conferred a fitness advantage in ancestral East Asian environments. The deletion allele reaches ~80% in East Asians versus ~22% in Africans — a striking disparity that is unlikely to reflect genetic drift alone at a locus of this size.

The connection to idiopathic pulmonary fibrosis (IPF)1010 idiopathic pulmonary fibrosis (IPF)
A progressive, irreversible lung scarring disease affecting ~3 in 10,000 people; median survival 3-5 years after diagnosis; etiology involves fibrogenic signaling in alveolar epithelium comes from GWAS evidence: Fingerlin et al. 20131111 Fingerlin et al. 2013
1,616 non-Hispanic white IPF cases and 4,683 controls plus replication cohort identified the 15q14-15 region containing IVD as a genome-wide significant IPF locus. The causal link between IVD expression and pulmonary fibrosis is likely mediated through isovaleryl-CoA accumulation driving mitochondrial dysfunction and fibrogenic signaling in alveolar epithelial cells — plausible but not directly demonstrated.

Practical Actions

For II carriers (insertion homozygous) — the ancestral, lower-expression genotype common in Africans (~78%) — two nutritional considerations are directly supported by the biochemistry. First, riboflavin adequacy is critical: IVD is exquisitely FAD-dependent, and since I-allele carriers already have lower IVD expression, maintaining maximal enzyme activity from available protein through riboflavin sufficiency is especially important. Second, avoiding pharmacological BCAA supplementation limits the isovaleryl-CoA substrate burden on a system running at reduced capacity.

For DI carriers — heterozygotes — the evidence is consistent with an intermediate phenotype. The same riboflavin consideration applies but with less urgency.

DD carriers have the highest IVD expression and most efficient leucine catabolism. No specific interventions are indicated beyond maintaining the riboflavin intake that enables IVD to function at its genetically determined maximum.

This variant does not relate to classical isovaleric acidemia (IVA), which is caused by biallelic pathogenic coding variants in IVD that abolish enzyme function entirely. The I allele of rs66791338 is a common regulatory variant affecting expression quantitatively, not a disease-causing mutation.

Interactions

rs66791338 is the primary functional variant within a three-variant regulatory haplotype at the IVD locus, co-inherited with rs10851395 and rs111540938. The high-expression haplotype carries the deletion at rs66791338 together with the ancestral alleles at the other two SNPs, producing a synergistic boost in IVD transcription. The nearby intronic variant rs2034650 is a widely studied tag variant in linkage disequilibrium with this haplotype, explaining why rs2034650 shows the IPF and isovalerylcarnitine associations despite not being directly functional.

No published gene-gene interactions between rs66791338 and variants in downstream leucine catabolism enzymes (3-methylcrotonyl-CoA carboxylase, electron transfer flavoprotein) have been identified, though such interactions are biologically plausible.

Nutrient Interactions

leucine altered_metabolism
riboflavin increased_need

Genotype Interpretations

What each possible genotype means for this variant.

DD High IVD Expression Beneficial

Deletion homozygous — highest IVD expression and most efficient leucine catabolism

Brown et al. 2024 (PMID 37930192) confirmed through bidirectional CRISPR/Cas9 editing that converting cells from insertion-homozygous to deletion-homozygous causally increases endogenous IVD expression. In the TwinsUK metabolomics cohort (n=4,678), this translated to a 0.088-unit decrease in isovalerylcarnitine (normalized to propionylcarnitine; r²=0.40, P<2×10⁻¹⁶) — meaning the deletion haplotype processes leucine-derived isovaleryl-CoA more efficiently, leaving less accumulation.

The strong positive selection signal in Japanese populations (JPT, 1000 Genomes Phase 3) centered on this locus suggests the high-expression IVD haplotype conferred a fitness advantage — possibly related to efficient energy extraction from high-protein diets historically prevalent in East Asian populations.

IVD is FAD-dependent: ensuring adequate riboflavin intake allows this genotype to operate at its full genetic potential. No supplementation beyond routine nutrition is indicated.

DI Intermediate IVD Expression Intermediate

One deletion allele — intermediate IVD expression and near-average leucine catabolism

For regulatory variants acting on transcription, heterozygotes typically produce intermediate mRNA levels — one allele drives higher transcription, the other lower. While CRISPR studies in Brown et al. 2024 (PMID 37930192) directly tested the homozygous states, the additive model is supported by the linear regression in the metabolomics cohort showing dose-dependent effects on isovalerylcarnitine across genotype groups.

The IPF GWAS signal at this locus (Fingerlin 2013, PMID 23583980) did not report separate heterozygote effect sizes; the effect was modeled additively, consistent with the biological mechanism.

Riboflavin adequacy becomes more relevant for DI carriers than for DD carriers, since one insertion allele partially constrains IVD expression. Maintaining FAD cofactor availability ensures that available IVD protein is catalytically active.

II Lower IVD Expression Reduced

Insertion homozygous — lowest IVD expression and least efficient leucine catabolism

Brown et al. 2024 (PMID 37930192) established through bidirectional CRISPR experiments that the insertion allele causally reduces IVD expression: converting insertion-homozygous cells to deletion-homozygous increased IVD mRNA, and the reverse conversion decreased it. In the TwinsUK metabolomics cohort (n=4,678), the insertion allele associated with higher isovalerylcarnitine (normalized to propionylcarnitine; r²=0.40, P<2×10⁻¹⁶) — consistent with reduced substrate turnover by lower-expression IVD.

This does not cause isovaleric acidemia (IVA), which requires biallelic pathogenic coding mutations abolishing IVD enzyme function. The I allele at rs66791338 reduces IVD expression quantitatively but retains functional enzyme — a metabolic disadvantage under leucine stress, not a disease-causing deficit.

The IPF association at this locus (Fingerlin 2013, PMID 23583980; Peljto 2015, PMID 25275363) nominally increases IPF susceptibility for insertion carriers relative to deletion carriers. The absolute risk from this variant alone is small — IPF affects ~3 in 10,000 people — but the nutritional implications are independently actionable.

Two vulnerabilities compound for II carriers: first, baseline IVD expression is genetically lower; second, IVD is exquisitely riboflavin-dependent, falling to 17% of control activity under riboflavin deficiency (Nagao & Tanaka 1992, PMID 1517228). Maintaining riboflavin adequacy keeps IVD activity as high as this genotype allows.